BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:59 PM
 | 
Jan 10, 2017
 |  BC Extra  |  Clinical News

Paper suggests Aravive compound could block Zika

In a study published Tuesday in Cell Reports, researchers from INSERM and Aravive Biologics Inc. (Houston, Texas) said Aravive’s preclinical candidate Aravive-S6 could protect glial cells from Zika infection.

Aravive-S6 is an Fc-fusion protein that blocks activation of the growth arrest-specific 6 (GAS6)-AXL receptor tyrosine...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >